Chemical Structure (Esomeprazole 8628 1)
Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 0615-8628
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 0615-8628). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Maintenance Of Healing Rates Of Ee In Adults By Month (study 177) (Esomeprazole 8628 2)
This is a description of a clinical trial evaluating the maintenance of percent of patients who had a scheduled visit for Esomeprazole Magnesium at different dosages (40mg, 20mg, and 10mg) and a placebo. The trial is conducted over a period of several months. The results show the efficacy of each dosage and the placebo in maintaining the scheduled visits.*
Figure 3: Maintenance Of Ee Healing Rates In Adults By Month (study 178) (Esomeprazole 8628 3)
This text seems to be a schedule of a visit, including information about the percentage maintained, with values ranging from 100% to 0%. It also mentions the dosage of Esomeprazole Magnesium in three different strengths, and a placebo group. The document refers to a study or trial that may involve the medication mentioned.*
Figure 4: Percent Of Patients Symptom-free Of Heartburn By Day (study 225) (Esomeprazole 8628 4)
This text appears to be referencing the effectiveness of Esomeprazole Magnesium Delayed-Release Capsules in providing symptom relief to patients. It states that 100 percent of patients were symptom-free when taking the capsules, compared to a placebo. The capsules are available in 20mg and 40mg doses. The study seems to involve tracking symptom status on different diary days, up to day 21.*
Figure 5: Percent Of Patients Symptom-free Of Heartburn By Day (study 226) (Esomeprazole 8628 5)
This is a comparison showing the percentage of patients who were symptom-free after taking Esomeprazole Magnesium Delayed-Release Capsules in doses of either 40 mg or 20 mg, as well as a placebo. The results indicate that 100% of patients who took Esomeprazole Magnesium Delayed-Release Capsules in both doses were symptom-free, while the placebo group had a lower percentage.*
Principal Display Panel (Esomeprazole 8628 6)
This text appears to be a detailed description of Esomeprazole Magnesium Delayed-Release Capsules USP in varying doses and lot numbers. It includes information on manufacturing details, package contents, dosages, storage instructions, and usage guidelines. The capsules contain esomeprazole magnesium equivalent to 20 mg or 40 mg of esomeprazole. The text mentions institutional use, package labeling trademarks, and the company involved in packaging. The presence of lot numbers suggests variations in production batches. Storage recommendations include a temperature range of 20°C to 25°C. Additionally, it indicates that the usual dosage information can be found in the accompanying package insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
